Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$96.13

0.18 (0.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02

AbbVie: Ibrutinib inhibited pre-germinal center B cells in trial

AbbVie announced new data on the biologic and cellular mechanisms of IMBRUVICA in patients with chronic graft-versus-host disease a potentially life-threatening consequence of an allogeneic stem cell or bone marrow transplant. New results showed ibrutinib selectively inhibited pre-germinal center B cells and follicular helper T cells that are believed to play a critical role in treating cGVHD. In addition, the data also showed that ibrutinib preserved immune memory and Th1 T cells, which suggests the potential for additional treatment benefit. These results were observed in a Phase 1b/2 trial. The data will be presented at the 59th American Society of Hematology Annual Meeting and Exposition on Dec. 11 in Atlanta IMBRUVICA is a first-in-class Bruton's tyrosine kinase inhibitor jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc. "These new data further underscore the potential benefit of IMBRUVICA in chronic graft-versus-host disease, and provide encouraging signs for its mechanism of action in a way that's meaningful to advancing treatment," said Lori Styles, M.D., Senior Medical Director and GVHD program clinical lead at Pharmacyclics LLC, an AbbVie company.

ABBV AbbVie
$96.13

0.18 (0.19%)

11/24/17
DBAB
11/24/17
NO CHANGE
Target $59
DBAB
Hold
Deutsche cuts Merck target to $59 on competition from AbbVie, GSK
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax. The stock closed Wednesday up 10c to $54.37. Demand trends for Merck's hepatitis C virus drug Zepatier have continued to decline as AbbVie's (ABBV) Mavyret has gained traction, Gilbert told investors in a research note. The analyst also assumes "significant pressure" on Merck's shingles vaccine Zostavax from the near-term competitive launch of GlaxoSmithKline's (GSK) Shingrix. Gilbert views Merck's risk/reward as fairly balanced and he keeps a Neutral rating on the shares.
12/04/17
BMOC
12/04/17
INITIATION
Target $31
BMOC
Outperform
InflaRx initiated with an Outperform at BMO Capital
BMO Capital analyst M. Ian Somaiya initiated InflaRx (IFRX) with an Outperform rating and a price target of $31. Somaiya says the positive Phase 2a data for the company's IFX-1 and regulatory path established by AbbVie's (ABBV) Humira de-risk the opportunity in hidradenitis suppurativa skin disorder, supporting his expectations for a positive Phase 2b data in the first half of FY19.
12/05/17
DBAB
12/05/17
NO CHANGE
Target $82
DBAB
Buy
Deutsche views Neurocrine's elagolix program as underappreciated
Deutsche Bank analyst Andrew Peters says that while the Ingrezza launch continues to be the primary focus for Neurocrine (NBIX) investors, the company's AbbVie-partnered (ABBV) elagolix program remains an "underappreciated aspect of the overall investment thesis." The analyst remains confident in the potential commercial opportunity for elagolix with data from the Phase 3 uterine fibroid study expected in early 2018 and the regulatory review in endometriosis ongoing. Recent expert checks have largely supported elagolix, Peters tells investors in a research note. The analyst raised his price target for Neurocrine shares to $82 from $79 and reiterates a Buy rating on the name.
12/05/17
LEER
12/05/17
NO CHANGE
Target $106
LEER
Outperform
AbbVie Risankizumab may be best in class for Psoriasis, says Leerink
Leerink analyst Geoffrey Porges notes that AbbVie reported positive data from the 4th of its four phase III trials that make up its pivotalprogram for its IL-23 antibody Risankizumab in patients with moderate-severe plaque psoriasis. The analyst believes risankizumab has a clearly differentiated profile in comparison to existing anti-TNF and IL-17s, making this an attractive option for use prior to other biologics once it becomes approved. Additionally, it appears risankizumab may offer incremental advantages over IL-23 competitor Tremfya in terms of efficacy and dosing schedule. He reiterates an Outperform rating and $106 price target on the shares.

TODAY'S FREE FLY STORIES

SPCB

SuperCom

$3.66

-0.03 (-0.81%)

10:47
01/16/18
01/16
10:47
01/16/18
10:47
Conference/Events
SuperCom management to meet with Drexel Hamilton »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

EIGR

Eiger BioPharmaceuticals

$16.00

0.65 (4.23%)

10:46
01/16/18
01/16
10:46
01/16/18
10:46
Recommendations
Eiger BioPharmaceuticals analyst commentary  »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 26

    Feb

  • 08

    Apr

KBH

KB Home

$36.03

-0.95 (-2.57%)

10:46
01/16/18
01/16
10:46
01/16/18
10:46
Conference/Events
KB Home management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

JKHY

Jack Henry

$123.38

0.7 (0.57%)

10:45
01/16/18
01/16
10:45
01/16/18
10:45
Conference/Events
Jack Henry management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:45
01/16/18
01/16
10:45
01/16/18
10:45
Conference/Events
Wolfe Research utilities analyst to hold a luncheon meeting »

Senior Utilities Analyst…

ECL

Ecolab

$137.42

-0.26 (-0.19%)

10:44
01/16/18
01/16
10:44
01/16/18
10:44
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 20

    Feb

CXP

Columbia Property

$21.93

0.08 (0.37%)

10:43
01/16/18
01/16
10:43
01/16/18
10:43
Conference/Events
Columbia Property management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 15

    Feb

TWTR

Twitter

$24.96

-0.45 (-1.77%)

, FB

Facebook

$179.37

-8.4 (-4.47%)

10:43
01/16/18
01/16
10:43
01/16/18
10:43
Hot Stocks
Former bear says buy Twitter as growth returns, takeover potential rises »

Aegis analyst Victor…

TWTR

Twitter

$24.96

-0.45 (-1.77%)

FB

Facebook

$179.37

-8.4 (-4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

FB

Facebook

$179.37

-8.4 (-4.47%)

, SNAP

Snap

$13.53

-0.585 (-4.15%)

10:41
01/16/18
01/16
10:41
01/16/18
10:41
Conference/Events
FBN Securities media analysts to hold a group luncheon »

Analysts host a Group…

FB

Facebook

$179.37

-8.4 (-4.47%)

SNAP

Snap

$13.53

-0.585 (-4.15%)

TWTR

Twitter

$24.96

-0.455 (-1.79%)

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

LNKD

Acquired by MSFT

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 18

    Mar

GE

General Electric

$18.14

-0.625 (-3.33%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Periodicals
GE seen as likely to embrace company breakup, CNBC reports »

General Electric is seen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

HMNY

Helios and Matheson

$7.64

-0.42 (-5.21%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Hot Stocks
MoviePass names Natasha Mulla CMO »

MoviePass, movie-theater…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$49.79

0.275 (0.56%)

10:40
01/16/18
01/16
10:40
01/16/18
10:40
Options
Notable interest in iShares Emerging Markets Fund options »

Notable interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$77.54

0.695 (0.90%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Hot Stocks
Citi CFO says U.S. Retail Services growing slightly above outlook »

CFO John Gerspach said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

VPG

Vishay Precision

$27.30

0.55 (2.06%)

10:38
01/16/18
01/16
10:38
01/16/18
10:38
Conference/Events
Vishay Precision management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 29

    Mar

SITE

SiteOne Landscape

$71.28

-0.2 (-0.28%)

10:37
01/16/18
01/16
10:37
01/16/18
10:37
Conference/Events
SiteOne Landscape management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

, RUT

Russell 2000 Index

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Technical Analysis
Technical View: Russell 2000 Index crosses above 1600, new life high »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$159.21

1.05 (0.66%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTH

LightPath

$2.42

0.09 (3.86%)

10:36
01/16/18
01/16
10:36
01/16/18
10:36
Conference/Events
LightPath management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

LOW

Lowe's

$104.00

3.14 (3.11%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Conference/Events
Lowe's management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

GE

General Electric

$18.17

-0.595 (-3.17%)

10:35
01/16/18
01/16
10:35
01/16/18
10:35
Periodicals
GE breakup likely, announcement may come this Spring, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

C

Citi

$77.56

0.715 (0.93%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi CFO: Trading-related…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
UBS leisure analyst holds an analyst/industry conference call »

Leisure Analyst Farley…

ITRN

Ituran

$35.30

1.25 (3.67%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Conference/Events
Ituran management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

  • 17

    Jan

C

Citi

$77.50

0.66 (0.86%)

10:33
01/16/18
01/16
10:33
01/16/18
10:33
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi sees core accrual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

AXTA

Axalta Coating

$31.99

-0.45 (-1.39%)

, UBS

UBS

$19.62

0.03 (0.15%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

AXTA

Axalta Coating

$31.99

-0.45 (-1.39%)

UBS

UBS

$19.62

0.03 (0.15%)

CS

Credit Suisse

$19.04

0.08 (0.42%)

NTR

Nutrien

$53.31

-0.12 (-0.22%)

CBM

Cambrex

$52.80

1.15 (2.23%)

DRNA

Dicerna

$8.42

-0.01 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

UA

Under Armour; also tag UAA

$13.13

-1.01 (-7.14%)

, UAA

Under Armour; also tag UA

$14.21

-0.91 (-6.02%)

10:32
01/16/18
01/16
10:32
01/16/18
10:32
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

UA

Under Armour; also tag UAA

$13.13

-1.01 (-7.14%)

UAA

Under Armour; also tag UA

$14.21

-0.91 (-6.02%)

VZ

Verizon

$51.84

-0.023 (-0.04%)

LMT

Lockheed Martin

$336.31

0.06 (0.02%)

COL

Rockwell Collins

$138.14

0.31 (0.22%)

SAVE

Spirit Airlines

$47.19

-1.07 (-2.22%)

FNSR

Finisar

$22.74

0.48 (2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 21

    Feb

  • 07

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.